BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28145609)

  • 41. Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions.
    Kelbæk H; Holmvang L; Richardt G; Eberli FR; Stella P; Buszman PE; Neumann FJ; Serruys PW; Windecker S; Widimský P; Belardi JA; Silber S
    EuroIntervention; 2015 Oct; 11(6):650-7. PubMed ID: 25033102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of poor initial TIMI flow in patients presenting with acute coronary syndrome.
    Nammas W; Pietilä M; Romppanen H; Sia J; DeBelder A; Karjalainen PP
    Scand Cardiovasc J; 2017 Oct; 51(5):248-254. PubMed ID: 28666394
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration.
    Chandrasekhar J; Kalkman DN; Aquino MB; Sartori S; Hájek P; Atzev B; Hudec M; Ong TK; Mates M; Borisov B; Warda HM; den Heijer P; Wojcik J; Iñiguez A; Coufal Z; Khashaba A; Schee A; Munawar M; Gerber RT; Yan BP; Tejedor P; Kala P; Liew HB; Lee M; Baber U; Vogel B; Dangas GD; Colombo A; de Winter RJ; Mehran R; ;
    Int J Cardiol; 2020 May; 307():17-23. PubMed ID: 32111358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents.
    Han Y; Xu B; Jing Q; Lu S; Yang L; Xu K; Li Y; Li J; Guan C; Kirtane AJ; Yang Y;
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1352-60. PubMed ID: 25440887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
    van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
    Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation.
    Natsuaki M; Morimoto T; Yamamoto E; Watanabe H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Hanaoka KI; Tanabe K; Kozuma K; Kimura T;
    PLoS One; 2020; 15(3):e0227612. PubMed ID: 32210433
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention.
    Loncar G; Barthelemy O; Berman E; Kerneis M; Petroni T; Payot L; Choussat R; Silvain J; Collet JP; Helft G; Montalescot G; Le Feuvre C
    Arch Cardiovasc Dis; 2015 Nov; 108(11):554-62. PubMed ID: 26184868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials.
    Gao Z; Zhang R; Xu B; Yang Y; Ma C; Li H; Chen S; Han Y; Yuan Z; Lansky AJ; Guan C; Leon MB; Gao R;
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():734-43. PubMed ID: 25678281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study.
    Džavík V; Kaul U; Guagliumi G; Chevalier B; Smits PC; Stuteville M; Li D; Sudhir K; Grube E
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E163-72. PubMed ID: 23225766
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
    Cutlip DE; Kereiakes DJ; Mauri L; Stoler R; Dauerman HL;
    JACC Cardiovasc Interv; 2015 Mar; 8(3):404-410. PubMed ID: 25703885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes.
    Brener SJ; Cristea E; Kirtane AJ; McEntegart MB; Xu K; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2013 Jan; 6(1):36-43. PubMed ID: 23266233
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
    Colleran R; Kufner S; Harada Y; Giacoppo D; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Schneider S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):367-374. PubMed ID: 27377301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration.
    Chandrasekhar J; Zeebregts D; Kalkman DN; Sartori S; Roumeliotis A; Aquino MB; de Wilde P; de Winter VC; Baber U; Woudstra P; Beijk MA; Hájek P; Atzev B; Hudec M; Ong TK; Mates M; Borisov B; Warda HM; den Heijer P; Wojcik J; Iniguez A; Lee M; Tijssen JG; Koch KT; Dangas GD; Colombo A; Mehran R; de Winter RJ;
    Cardiovasc Revasc Med; 2020 Dec; 21(12):1542-1547. PubMed ID: 32507695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study.
    Hermiller JB; Applegate RJ; Baird C; Butler MM; Rutledge D; Wang J; Kakarala K; Krucoff MW; Sudhir K
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):62-70. PubMed ID: 26399687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions).
    Kandzari DE; Kini AS; Karmpaliotis D; Moses JW; Tummala PE; Grantham JA; Orr C; Lombardi W; Nicholson WJ; Lembo NJ; Popma JJ; Wang J; Larracas C; Rutledge DR
    JACC Cardiovasc Interv; 2015 May; 8(6):761-769. PubMed ID: 25912400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.